Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company headquartered in Research Triangle Park, North Carolina, is set to participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:00 p.m. ET. This engagement will be presented in a fireside chat format, accessible to investors and interested parties via a live webcast. The webcast can be found at [this link](https://event.webcasts.com/starthere.jsp?ei=1744934&tp_key=8b0c843aa1) and will be archived for later viewing on the Company’s website.

Fennec Pharmaceuticals is primarily focused on addressing ototoxicity, a serious side effect experienced by cancer patients undergoing cisplatin-based chemotherapy. The company’s flagship product, PEDMARK®, received FDA approval in September 2022, followed by approvals from the European Commission in June 2023 and the UK in October 2023, where it is marketed as PEDMARQSI. In March 2024, Fennec entered an exclusive licensing agreement with Norgine Pharmaceuticals Ltd., allowing the latter to commercialize PEDMARQSI across Europe, the U.K., Australia, and New Zealand, where it is already available in Germany and the U.K.

PEDMARK has earned Orphan Drug Exclusivity in the U.S., while PEDMARQSI has Pediatric Use Marketing Authorization in the EU, providing it with a robust data and market protection of up to ten years. Additionally, Fennec holds patents that extend protection for PEDMARK until 2039 in both the U.S. and internationally. Investors interested in Fennec's advancements and future plans are encouraged to join the upcoming conference session and visit their website for further details.

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) is poised to gain attention as it participates in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The company's focus on mitigating ototoxicity in cancer patients receiving cisplatin-based chemotherapy through its product, PEDMARK® (branded as PEDMARQSI in Europe), positions it strategically in a niche yet critical segment of oncology care.

Since gaining FDA approval in September 2022 and subsequent approvals in Europe and the UK, Fennec has demonstrated significant progress in commercializing PEDMARK. The exclusive licensing agreement with Norgine Pharmaceuticals for key markets further strengthens its distribution capabilities, heralding potential revenue growth. The fact that PEDMARK has Orphan Drug Exclusivity in the U.S. and extended market protections in Europe highlights its competitive edge and the likelihood of sustaining market share over the long term.

Investors should closely monitor the feedback from the fireside chat at the upcoming conference, which could provide insights into Fennec's growth strategy and upcoming developments. With an innovative product in a specialized medical niche, coupled with robust protective patents until 2039, Fennec appears to have a solid foundation.

Market analysts may view the current stock price as an attractive entry point, particularly if the company continues to deliver strong updates regarding sales performance and market expansion. Additionally, the archived replay of the event may serve as a valuable resource for further analysis.

In conclusion, investors should consider Fennec Pharmaceuticals as a potential buy, especially if the upcoming presentations reflect confidence in its growth trajectory and operational execution. The focus on addressing unmet medical needs in oncology could yield significant long-term benefits for Fennec and its stakeholders.